29989057|t|Aberrant Levels of Cystatin C in Amyotrophic Lateral Sclerosis: a Systematic Review and Meta Analysis.
29989057|a|Evidences suggest that Cystatin C (Cys C) levels might be a biomarker in amyotrophic lateral sclerosis (ALS) diagnosis, but the conclusion is still in doubts. We conducted a systematic review and meta analysis of Cys C levels in cerebrospinal cord fluid (CSF) and peripheral blood of patients with ALS in order to further confirm whether or not Cys C levels is a biomarker in ALS diagnosis. The English relevant studies without year limitation were systematically searched in PubMed, EMBASE, Web of Science databases. The searched term contained "Amyotrophic Lateral Sclerosis" or "Motor Neuron Diseases" and "Cystatin C" and "Cerebrospinal fluid" or "CSF" or "Biomarker" or "Serum" or "Plasma" or "Blood". Observational studies reporting the associations between Cys C levels and ALS patients were selected to conduct a systematic review and meta analysis. Two reviewers performed the selection of this study independently. The Newcastle-Ottawa Scale assesses the quality and risk of bias of selected studies. Estimates were pooled using a random-effects model. The Cys C levels of CSF or peripheral blood in ALS patients compared with health controls (HCs) and several relevant neurodegenerative diseases (NDDs). Sixteen studies were included in our systematic review, 9 of them were selected to perform the meta analysis. Of these, eight studies measured Cys C levels in CSF and three studies measured it in blood. Cys C levels in CSF were significantly lower in ALS patients than in HCs (Hedge's g = -1.398, 95%CI: -2.43 to -0.36; p = 0.008), but there was no statistical difference between ALS patients and several relevant NDDs. No statistically significant difference in the Cys C levels of blood in the comparison between ALS and HCs. The correlation meta analysis presented no significant correlation between Cys C levels in CSF and age or disease duration respectively. Cys C levels significantly decrease in the CSF of ALS patients, but are not a specific biomarker for this disease. Cys C levels in CSF might be an auxiliary diagnostic biomarker of ALS.
29989057	19	29	Cystatin C	Gene	1471
29989057	33	62	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
29989057	126	136	Cystatin C	Gene	1471
29989057	138	143	Cys C	Gene	1471
29989057	176	205	amyotrophic lateral sclerosis	Disease	MESH:D000690
29989057	207	210	ALS	Disease	MESH:D000690
29989057	316	321	Cys C	Gene	1471
29989057	387	395	patients	Species	9606
29989057	401	404	ALS	Disease	MESH:D000690
29989057	448	453	Cys C	Gene	1471
29989057	479	482	ALS	Disease	MESH:D000690
29989057	650	679	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
29989057	685	706	Motor Neuron Diseases	Disease	MESH:D016472
29989057	713	723	Cystatin C	Gene	1471
29989057	867	872	Cys C	Gene	1471
29989057	884	887	ALS	Disease	MESH:D000690
29989057	888	896	patients	Species	9606
29989057	1170	1175	Cys C	Gene	1471
29989057	1213	1216	ALS	Disease	MESH:D000690
29989057	1217	1225	patients	Species	9606
29989057	1283	1309	neurodegenerative diseases	Disease	MESH:D019636
29989057	1311	1315	NDDs	Disease	MESH:D019636
29989057	1461	1466	Cys C	Gene	1471
29989057	1521	1526	Cys C	Gene	1471
29989057	1569	1572	ALS	Disease	MESH:D000690
29989057	1573	1581	patients	Species	9606
29989057	1698	1701	ALS	Disease	MESH:D000690
29989057	1702	1710	patients	Species	9606
29989057	1732	1736	NDDs	Disease	MESH:D019636
29989057	1785	1790	Cys C	Gene	1471
29989057	1833	1836	ALS	Disease	MESH:D000690
29989057	1921	1926	Cys C	Gene	1471
29989057	1983	1988	Cys C	Gene	1471
29989057	2033	2036	ALS	Disease	MESH:D000690
29989057	2037	2045	patients	Species	9606
29989057	2098	2103	Cys C	Gene	1471
29989057	2164	2167	ALS	Disease	MESH:D000690
29989057	Association	MESH:D000690	1471

